FibroGen Financials
| FGEN Stock | MXN 7.20 1.52 17.43% |
FibroGen |
Understanding current and past FibroGen Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of FibroGen's financial statements are interrelated, with each one affecting the others. For example, an increase in FibroGen's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in FibroGen's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of FibroGen. Check FibroGen's Beneish M Score to see the likelihood of FibroGen's management manipulating its earnings.
FibroGen Stock Summary
FibroGen competes with Costco Wholesale, Cognizant Technology, McEwen Mining, Monster Beverage, and Air Transport. FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company was incorporated in 1993 and is headquartered in San Francisco, California. FibroGen operates under Biotechnology classification in Mexico and is traded on Mexico Stock Exchange. It employs 461 people.| Foreign Associate | USA |
| Instrument | Mexico Stock View All |
| Exchange | Mexican Exchange |
| Business Address | 409 Illinois Street, |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | www.fibrogen.com |
| Phone | 415 978 1200 |
| Currency | MXN - Mexican Peso |
You should never invest in FibroGen without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of FibroGen Stock, because this is throwing your money away. Analyzing the key information contained in FibroGen's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
FibroGen Key Financial Ratios
FibroGen's financial ratios allow both analysts and investors to convert raw data from FibroGen's financial statements into concise, actionable information that can be used to evaluate the performance of FibroGen over time and compare it to other companies across industries.FibroGen Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining FibroGen's current stock value. Our valuation model uses many indicators to compare FibroGen value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across FibroGen competition to find correlations between indicators driving FibroGen's intrinsic value. More Info.FibroGen is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value FibroGen by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for FibroGen's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.FibroGen Systematic Risk
FibroGen's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. FibroGen volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on FibroGen correlated with the market. If Beta is less than 0 FibroGen generally moves in the opposite direction as compared to the market. If FibroGen Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one FibroGen is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of FibroGen is generally in the same direction as the market. If Beta > 1 FibroGen moves generally in the same direction as, but more than the movement of the benchmark.
FibroGen March 20, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of FibroGen help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of FibroGen. We use our internally-developed statistical techniques to arrive at the intrinsic value of FibroGen based on widely used predictive technical indicators. In general, we focus on analyzing FibroGen Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build FibroGen's daily price indicators and compare them against related drivers.
| Downside Deviation | 10.76 | |||
| Information Ratio | 0.0529 | |||
| Maximum Drawdown | 66.35 | |||
| Value At Risk | (7.77) | |||
| Potential Upside | 13.89 |
Additional Tools for FibroGen Stock Analysis
When running FibroGen's price analysis, check to measure FibroGen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy FibroGen is operating at the current time. Most of FibroGen's value examination focuses on studying past and present price action to predict the probability of FibroGen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move FibroGen's price. Additionally, you may evaluate how the addition of FibroGen to your portfolios can decrease your overall portfolio volatility.